表紙
市場調査レポート

HIV治療薬の世界市場:2015年〜2019年

Global HIV Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 226022
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
HIV治療薬の世界市場:2015年〜2019年 Global HIV Drugs Market 2015-2019
出版日: 2015年10月14日 ページ情報: 英文 84 Pages
概要

世界のHIV治療薬市場は、2014年から2019年にかけて4.52%のCAGRで成長すると予測されています。

当レポートでは、世界におけるHIV治療薬市場について調査し、市場規模とその予測、市場の成長要因や課題、主要ベンダーのプロファイルなど、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市場調査手法

第4章 イントロダクション

第5章 市場情勢

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第6章 市場区分:薬剤クラス別

第7章 世界のマルチクラス配合剤市場

第8章 世界のヌクレオシド逆転写酵素阻害剤市場

第9章 世界の非ヌクレオシド逆転写酵素阻害剤市場

第10章 世界のプロテアーゼ阻害薬市場

第11章 世界の融合阻害剤市場

第12章 世界の侵入阻害剤市場:CCR5受容体遮断剤市場

第13章 世界のHIVインテグラーゼストランド転写阻害剤

第14章 地域区分

  • 世界のHIV治療薬市場区分:地域別

第15章 市場成長促進因子

  • 資金の増加
  • 患者人口の増加
  • 医療のアンメットニーズ
  • 政府によるイニシアチブ

第16章 成長因子の影響

第17章 市場課題

  • 特許の失効
  • 社会的な不名誉
  • 治療薬の副作用
  • 病気の診断における合併症

第18章 促進因子・課題の影響

第19章 市場動向

  • 社会認識の上昇
  • 戦略的アライアンス
  • 新しいアプローチ

第20章 米国政府:HIV資金

第21章 ベンダー情勢

  • 競合状況
  • 市場シェア分析
  • その他の有望ベンダー

第22章 主要ベンダーの分析

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

第23章 付録

第24章 Technavioについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR7469

About HIV

HIV is a type of retrovirus that causes infection in human beings. AIDS is a life-threatening disease caused by this virus. In this disease certain white blood cells (lymphocytes) are destroyed, resulting in the loss of the body's ability to protect itself against infections. The major route of transmission of HIV infection is unprotected sex, contaminated needle, breast milk, and infected blood. HIV attacks the body's white blood cells, specifically a subset called CD4 or helper T cells. The anti-retroviral therapy is used to treat the patient and help the immune system fight the infection. This is mainly used to keep the level of the HIV low in the body.

Technavio's analysts forecast the global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection.

Based on the class of drugs, the market is segmented as follows:

  • Multi-class combination products
  • Nucleoside reverse transcriptase inhibitors
  • Non-nucleoside reverse transcriptase inhibitors
  • Protease inhibitors
  • Fusion inhibitors
  • Entry inhibitors - CCR5 co-receptor antagonist
  • HIV integrase strand transfer inhibitors

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Technavio's report, Global HIV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

Other Prominent Vendors

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Cipla
  • Daiichi Sankyo
  • Emcure
  • F. Hoffmann-La Roche
  • Hetero Drugs
  • Mylan
  • Pfizer
  • Shionogi
  • Teva Pharmaceutical Industries

Market driver

  • Inflow of funds
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries
  • For a full, detailed list, view our report

Market trend

  • Increasing public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by drug class

PART 07: Global multi-class combination products market

  • Global multi-class combination products market

PART 08: Global nucleoside reverse transcriptase inhibitors market

  • Global nucleoside reverse transcriptase inhibitors market

PART 09: Global non-nucleoside reverse transcriptase inhibitors market

  • Global non-nucleoside reverse transcriptase inhibitors market

PART 10: Global protease inhibitors market

  • Global protease inhibitors market

PART 11: Global fusion inhibitors market

  • Global fusion inhibitors market

PART 12: Global entry inhibitors - CCR5 co-receptor antagonist market

  • Global entry inhibitors - CCR5 co-receptor antagonist market

PART 13: Global HIV integrase strand transfer inhibitors market

  • Global HIV integrase strand transfer inhibitors market

PART 14: Geographical segmentation

  • Global HIV drugs market segmentation by geography

PART 15: Market drivers

  • Increased funding
  • Rise in patient population
  • Unmet medical needs
  • Initiatives by governments

PART 16: Impact of drivers

PART 17: Market challenges

  • Expiry of patents
  • Associated social stigma
  • Side effects of drugs
  • Complications in disease diagnosis

PART 18: Impact of drivers and challenges

PART 19: Market trends

  • Rise in public awareness
  • Strategic alliances
  • Novel approaches

PART 20: US Government: Funding for HIV

PART 21: Vendor landscape

  • Competitive scenario
  • Market share analysis
  • Other prominent vendors

PART 22: Key vendor analysis

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

PART 23: Appendix

  • List of abbreviations

PART 24: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global HIV drugs market 2014-2019 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Global HIV drugs market segmentation by drug class 2014
  • Exhibit 05: Global HIV drugs market segmentation by drug class 2014-2019 ($ millions)
  • Exhibit 06: Global multi-class combination products market 2014-2019 ($ millions)
  • Exhibit 07: Global nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
  • Exhibit 08: Global non-nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
  • Exhibit 09: Global protease inhibitors market 2014-2019 ($ millions)
  • Exhibit 10: Global fusion inhibitors market 2014-2019 ($ millions)
  • Exhibit 11: Global entry inhibitors - CCR5 co-receptor antagonist market 2014-2019 ($ millions)
  • Exhibit 12: Global HIV integrase strand transfer inhibitors market 2014-2019 ($ millions)
  • Exhibit 13: Global HIV drugs market segmentation by geography 2014
  • Exhibit 14: Global HIV drugs market segmentation by geography 2014-2019 ($ millions)
  • Exhibit 15: HIV drugs market in Americas 2014-2019 ($ millions)
  • Exhibit 16: HIV drugs market in EMEA 2014-2019 ($ millions)
  • Exhibit 17: HIV drugs market in APAC 2014-2019 ($ millions)
  • Exhibit 18: Assistance from donor governments for HIV treatment 2013
  • Exhibit 19: Global HIV statistics 2014
  • Exhibit 20: Impact of drivers
  • Exhibit 21: Impact of drivers and challenges
  • Exhibit 22: Funding by the US government for HIV 2010-2016 ($ billions)
  • Exhibit 23: Funding by the US government for domestic treatment and care of HIV 2010-2016 ($ billions)
  • Exhibit 24: Bristol-Myers Squibb: Revenue of Reyataz 2012-2014 ($ billions)
  • Exhibit 25: Bristol-Myers Squibb: Revenue of Sustiva 2012-2014 ($ billions)
  • Exhibit 26: Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
  • Exhibit 27: Gilead Sciences: Revenue of Truvada 2012-2014 ($ billions)
  • Exhibit 28: Gilead Sciences: Revenue of Emtriva 2012 and 2013 ($ millions)
  • Exhibit 29: Gilead Sciences: Revenue of Atripla 2012-2014 ($ billions)
  • Exhibit 30: Gilead Sciences: Revenue of Complera/Eviplera 2012-2014 ($ millions)
  • Exhibit 31: Gilead Sciences: Revenue of Viread 2012-2014 ($ millions)
  • Exhibit 32: GlaxoSmithKline: Revenue of Combivir 2012-2014 ($ millions)
  • Exhibit 33: GlaxoSmithKline: Revenue of Trizivir 2012-2014 ($ millions)
  • Exhibit 34: GlaxoSmithKline: Revenue of Agenerase and Lexiva 2012-2014 ($ millions)
  • Exhibit 35: GlaxoSmithKline: Revenue of Tivicay 2013-2014 ($ millions)
  • Exhibit 36: Johnson & Johnson: Revenue of Edurant 2012-2014 ($ millions)
  • Exhibit 37: Johnson & Johnson: Revenue of Prezista 2012-2014 ($ billions)
  • Exhibit 38: Merck: Revenue of Isentress 2012-2014 ($ billions)
Back to Top